jorveza
dr. falk pharma gmbh - budesonide - esophageal bolezni - antidiarrheals, črevesne protivnetna / antiinfective agenti - zdravilo jorveza je indicirano za zdravljenje eozinofilnega esophagitisa (eoe) pri odraslih (starejše od 18 let).
takhzyro
takeda pharmaceuticals international ag ireland branch - lanadelumab - angioedem, dedno - other hematological agents - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in patients aged 2 years and older.
namuscla
lupin europe gmbh - mexiletine hydrochloride - myotonic motnje - srčna terapija - namuscla je primerna za simptomatsko zdravljenje myotonia pri odraslih bolnikih z ne-dystrophic myotonic motnje.
trecondi
medac gesellschaft für klinische spezialpräparate mbh - treosulfan - hematopoetična presaditev izvornih celic - antineoplastična sredstva - treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (allohsct) in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases.
trepulmix
scipharm sàrl - treprostinil natrijev - hipertenzija, pljučnica - antitrombotična sredstva - treatment of adult patients with who functional class (fc) iii or iv and:inoperable chronic thromboembolic pulmonary hypertension (cteph), orpersistent or recurrent cteph after surgical treatmentto improve exercise capacity.
isturisa
recordati rare diseases - osilodrostat fosfat - cushingov sindrom - kortikosteroidi za sistemsko uporabo - isturisa je primerna za zdravljenje endogenih cushingov sindrom pri odraslih.
idefirix
hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - imunosupresivi - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.
adakveo
novartis europharm limited - crizanlizumab - anemija, srčna celica - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.
elzonris
stemline therapeutics b.v. - tagraxofusp - lymphoma - antineoplastična sredstva - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).
sogroya
novo nordisk a/s - somapacitan - rast - hipofize in hipotalamični hormoni in analogi - sogroya is indicated for the replacement of endogenous growth hormone (gh) in children aged 3 years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric ghd), and in adults with growth hormone deficiency (adult ghd).